中华实验和临床感染病杂志(电子版)
中華實驗和臨床感染病雜誌(電子版)
중화실험화림상감염병잡지(전자판)
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2014年
1期
42-44
,共3页
邹远妩%周祎%高漫%李王平
鄒遠嫵%週祎%高漫%李王平
추원무%주의%고만%리왕평
非结核分枝杆菌%抗结核药%耐药
非結覈分枝桿菌%抗結覈藥%耐藥
비결핵분지간균%항결핵약%내약
Nontuberculosis mycobacteria (NTM)%Anti-tuberculosis drug%Drug resistance
目的:观察分析非结核分枝杆菌(NTM)的耐药情况。方法收集本院分枝杆菌培养阳性并鉴定为非结核分枝杆菌的病例,并对其药效结果进行分析。结果320例分枝杆菌培养阳性病例中,54例为非结核分枝杆菌,占16.9%,对二线抗结核药物阿米卡星(AK),卷曲霉素(CPM),对氨基水杨酸钠(PAS),莫西沙星(MFX),左氧氟沙星(LFX)和丙硫异烟胺(TH1321)均有不同程度的耐药,耐药率高达87.0%,且大多数呈现多耐药。结论非结核分枝杆菌对抗结核药呈现耐药现象,故临床用药困难,对临床抗结核治疗效果不佳或疑似NTM肺病的患者应及早做痰培养、菌型鉴定及药物敏感试验并寻求其他有效的治疗方法。
目的:觀察分析非結覈分枝桿菌(NTM)的耐藥情況。方法收集本院分枝桿菌培養暘性併鑒定為非結覈分枝桿菌的病例,併對其藥效結果進行分析。結果320例分枝桿菌培養暘性病例中,54例為非結覈分枝桿菌,佔16.9%,對二線抗結覈藥物阿米卡星(AK),捲麯黴素(CPM),對氨基水楊痠鈉(PAS),莫西沙星(MFX),左氧氟沙星(LFX)和丙硫異煙胺(TH1321)均有不同程度的耐藥,耐藥率高達87.0%,且大多數呈現多耐藥。結論非結覈分枝桿菌對抗結覈藥呈現耐藥現象,故臨床用藥睏難,對臨床抗結覈治療效果不佳或疑似NTM肺病的患者應及早做痰培養、菌型鑒定及藥物敏感試驗併尋求其他有效的治療方法。
목적:관찰분석비결핵분지간균(NTM)적내약정황。방법수집본원분지간균배양양성병감정위비결핵분지간균적병례,병대기약효결과진행분석。결과320례분지간균배양양성병례중,54례위비결핵분지간균,점16.9%,대이선항결핵약물아미잡성(AK),권곡매소(CPM),대안기수양산납(PAS),막서사성(MFX),좌양불사성(LFX)화병류이연알(TH1321)균유불동정도적내약,내약솔고체87.0%,차대다수정현다내약。결론비결핵분지간균대항결핵약정현내약현상,고림상용약곤난,대림상항결핵치료효과불가혹의사NTM폐병적환자응급조주담배양、균형감정급약물민감시험병심구기타유효적치료방법。
Objective To evaluate the drug resistance actuality of nontuberculosis Mycobacteria (NTM). Methods Analysis was carried out on anti-tuberculosis (TB) drug efifcacy in the patients who were conifrmed to be Mycobacterial culture positive but not Mycobacterium tuberculosis cases. Results There were 54 cases of nontuberculosis Mycobacteria among 320 cases of Mycobacteria culture positive cases, accounting for 16.9%, exhibited different degrees of drug tolerance to second-line anti-TB drugs, such as amikacin (AK), capreomycin (CPM), sodium para-aminosalicylate (PAS), moxilfoxacin (MFX), levolfoxacin (LFX) and protionamide (TH1321), and most of which presented multidrug resistance. Conclusions Resistance of nontuberculosis Mycobacteria to anti-TB drug leads to the dififculties of clinical application. Sputum culture, bacteria identiifcation, drug sensitive test and other treatments should be adopted for patients with unacceptable clinical anti-TB treatment effects or patients with suspected NTM lung disease.